Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 4.3% After Analyst Downgrade

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price traded down 4.3% on Monday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock traded as low as $43.64 and last traded at $42.99. 63,402 shares were traded during trading, a decline of 90% from the average session volume of 640,435 shares. The stock had previously closed at $44.90.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 6,901 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $50.00, for a total transaction of $345,050.00. Following the sale, the director owned 12,546 shares of the company’s stock, valued at $627,300. This represents a 35.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at approximately $1,280,146.42. The trade was a 19.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,479 shares of company stock valued at $2,832,812 over the last quarter. 53.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the second quarter valued at $31,000. USA Financial Formulas bought a new position in Kiniksa Pharmaceuticals International during the third quarter valued at $32,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter valued at $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter valued at $41,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

The stock’s fifty day moving average price is $46.10 and its 200 day moving average price is $42.72. The stock has a market capitalization of $3.25 billion, a P/E ratio of 57.36 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) earnings per share. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.09 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.